剪接因子PUF60——基因治疗的新靶点

doi:10.3760/cma.j.issn.1673-422X.2017.07.013

国际肿瘤学杂志 ›› 2017, Vol. 44 ›› Issue (7): 531-533.doi: 10.3760/cma.j.issn.1673-422X.2017.07.013

剪接因子PUF60——基因治疗的新靶点

张灿灿，张蓉

201499上海，锦州医科大学奉贤医院研究生培训基地妇产科（张灿灿）；南方医科大学附属奉贤医院妇产科（张蓉）

收稿日期:2016-12-12 出版日期:2017-07-08 发布日期:2017-06-20
通讯作者: 张蓉 E-mail:rongzhang1965@163.com
基金资助:
国家自然科学基金（81672587,81472445）

A new target for gene therapy—splicing factor PUF60

Zhang Cancan, Zhang Rong

Department of Obsterics and Gynecology, Fengxian Hospital Graduate Training Base, Jinzhou Medical University, Shanghai 201499, China

Received:2016-12-12 Online:2017-07-08 Published:2017-06-20
Contact: Zhang Rong E-mail:rongzhang1965@163.com
Supported by:
National Natural Science Foundation of China (81672587, 81472445)

摘要/Abstract

摘要： 聚-U结合剪接因子60 KDa（PUF60）是一个与U2相关的剪接因子，在剪接体组装早期的3′剪接位点的识别中发挥重要作用。PUF60蛋白高表达与结直肠癌、卵巢癌、胃癌、肝癌等多种肿瘤的发生相关，其可通过人转录因子Ⅱ调控cmyc的表达。PUF60抗体可以在早期和复发肿瘤患者的血清中检测到，术前的检出率明显高于术后。PUF60可作为肿瘤诊断的联合或独立检测指标，为基因治疗提供新的靶点。

关键词: 肿瘤, 基因, myc, DNA, 重组

Abstract: Poly(U) binding splicing factor 60 KDa (PUF60), a U2related splicing factor that facilitates 3′splicesite recognition at the early stage of spliceosome assembly. High expression of PUF60 is related to the occurrence of multiple tumors, such as colorectal cancer, ovarian cancer, gastric cancer, liver cancer, et al. PUF60 can regulate the expression of cmyc through the corehuman transcription factor Ⅱ basal transcription factor. AntiPUF60 antibodies are detected in the sera of patients with earlystage and recurrent tumor, and the levels are significantly decreased after the operation. PUF60 can be used as a combined or independent test index for the diagnosis of cancer, which can be a potential new target for gene therapy.

Key words: Neoplasms, Genes, myc, DNA, recombinant

张灿灿，张蓉. 剪接因子PUF60——基因治疗的新靶点[J]. 国际肿瘤学杂志, 2017, 44(7): 531-533.

Zhang Cancan, Zhang Rong. A new target for gene therapy—splicing factor PUF60[J]. Journal of International Oncology, 2017, 44(7): 531-533.

参考文献

［1］ Rahmutulla B, Matsushita K, Satoh M, et al. Alternative splicing of FBPinteracting repressor coordinates cMyc, P27Kip1/cyclinE and Ku86/XRCC5 expression as a molecular sensor for bleomycininduced DNA damage pathway［J］. Oncotarget, 2014, 5(9): 2404-2417. DOI: 10.18632/oncotarget.1650. ［2］ Ren C, Chen T, Sun H, et al. The first echinoderm polyUbinding factor 60 kDa (PUF60) from sea cucumber (stichopus monotuberculatus): molecular characterization, inducible expression and involvement of apoptosis［J］. Fish Shellfish Immunol, 2015, 47(1): 196-204. DOI: 10.1016/j.fsi.2015.09.001. ［3］ Chen J, Weiss WA. Alternative splicing in cancer: implications for biology and therapy［J］. Oncogene, 2015, 34(1): 1-14. DOI: 10.1038/onc.2013.570. ［4］ Kralovicova J, Knut M, Cross NC, et al. Identification of U2AF(35)dependent exons by RNASeq reveals a link between 3′ splicesite organization and activity of U2AFrelated proteins［J］. Nucleic Acids Res, 2015, 43(7): 3747-3763. DOI: 10.1093/nar/gkv194. ［5］ Matsushita K, Tamura M, Tanaka N, et al. Interactions between SAP155 and FUSEbinding proteininteracting repressor bridges cMyc and P27Kip1 expression［J］. Mol Cancer Res, 2013, 11(7): 689-698. DOI: 10.1158/1541-7786.MCR-12-0673. ［6］ Sveen A, Kilpinen S, Ruusulehto A, et al. Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes［J］. Oncogene, 2016, 35(19): 2413-2427. DOI: 10.1038/onc.2015.318. ［7］ Upheber S, Karle A, Miller J, et al. Alternative splicing of KAI1 abrogates its tumorsuppressive effects on integrin αvβ3mediated ovarian cancer biology［J］. Cell Signal, 2015, 27(3): 652-662. DOI: 10.1016/j.cellsig.2014.11.028. ［8］ Choi JW, Lee JW, Kim JK, et al. Splicing variant of AIMP2 as an effective target against chemoresistant ovarian cancer［J］. J Mol Cell Biol, 2012, 4(3): 164173. DOI: 10.1093/jmcb/mjs018. ［9］ Matsushita K, Tomonaga T, Shimada H, et al. An essential role of alternative splicing of cmyc suppressor FUSEbinding proteininteracting repressor in carcinogenesis［J］. Cancer Res, 2006, 66(3): 1409-1417. DOI: 10.1158/0008-5472.CAN-04-4459. ［10］ Kobayashi S, Hoshino T, Hiwasa T, et al. AntiFIRs (PUF60) autoantibodies are detected in the sera of earlystage colon cancer patients［J］. Oncotarget, 2016, 7(50): 82493-82503. DOI: 10.18632/oncotarget.12696. ［11］ Cheng L, Wang P, Yang S, et al. Identification of genes with a correlation between copy number and expression in gastric cancer［J］. BMC Med Genomics, 2012, 5: 14. DOI: 10.1186/1755-87945-14. ［12］ Huang H, Han Y, Wu J, et al. Establishment of drug resistant cell line of MGC803 and analysis of differential secretome［J］. Beijing Da Xue Xue Bao, 2014, 46(2): 183-189. ［13］ Malz M, Bovet M, Samarin J, et al. Overexpression of far upstream element (FUSE) binding protein (FBP)interacting repressor (FIR) supports growth of hepatocellular carcinoma［J］. Hepatology, 2014, 60(4): 12411250. DOI: 10.1002/hep.27218. ［14］ Ramakrishna M, Williams LH, Boyle SE, et al. Identification of candidate growth promoting genes in ovarian cancer through integrated copy number and expression analysis［J］. PLoS One, 2010, 5(4): e9983. DOI: 10.1371/journal.pone.0009983. ［15］ Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma［J］. Nature, 2011, 474(7353): 609-615. DOI: 10.1038/nature10166. ［16］ Dauber A, Golzio C, Guenot C, et al. SCRIB and PUF60 are primary drivers of the multisystemic phenotypes of the 8q24.3 copynumber variant［J］. Am J Hum Genet, 2013, 93(5): 798-811. DOI: 10.1016/j.ajhg.2013.09.010. ［17］ Wells C, Spaggiari E, Malan V, et al. First fetal case of the 8q24.3 contiguous genes syndrome［J］. Am J Med Genet A, 2016, 170A(1): 239-242. DOI: 10.1002/ajmg.a.37411. ［18］ Fiorentino DF, Presby M, Baer AN, et al. PUF60: a prominent new target of the autoimmune response in dermatomyositis and Sjgren′s syndrome［J］. Ann Rheum Dis, 2016, 75(6): 1145-1151. DOI: 10.1136/annrheumdis-2015-207509.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.

剪接因子PUF60——基因治疗的新靶点

A new target for gene therapy—splicing factor PUF60

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价